9月29日 - ** 镜片制造商Staar Surgical（STAA.O）的股价在盘前交易中上涨5.1%，至21.9美元
** 证券公司斯蒂费尔认为，随着该公司EVO+人工晶体在中国市场的推广以及国际需求的复苏，其营收有望实现上行空间；将该股评级从“持有”上调至“买入”
** 将目标价从28美元上调至31美元，较上一交易日收盘价溢价49%
** 该机构表示，鉴于中国市场持续强劲增长以及海外需求改善，市场对未来销售额的预期过低
** 斯蒂费尔指出，该公司ICL技术组合的增长潜力被低估，包括在大型年龄相关视力疾病(老花眼) 市场中的机遇
** 12家券商中有4家给予该股“买入”或更高评级，7家给予“持有”评级，1家给予“卖出”评级；目标价中位数为27美元
** 截至上个交易日收盘，该股年内累计下跌9.6%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.